Caribou Biosciences, Inc.
NASDAQ:CRBU
2.08 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 34.477 | 13.851 | 9.598 | 12.361 | 5.788 |
| Cost of Revenue
| 3.525 | 3.641 | 0.984 | 34.425 | 23.635 |
| Gross Profit
| 30.952 | 10.21 | 8.614 | -22.064 | -17.847 |
| Gross Profit Ratio
| 0.898 | 0.737 | 0.897 | -1.785 | -3.083 |
| Reseach & Development Expenses
| 112.075 | 82.23 | 52.255 | 34.425 | 23.635 |
| General & Administrative Expenses
| 38.461 | 38.02 | 24.322 | 14.06 | 16.458 |
| Selling & Marketing Expenses
| -3.525 | 0 | 0 | 0 | 0 |
| SG&A
| 34.936 | 38.02 | 24.322 | 14.06 | 16.458 |
| Other Expenses
| 14.188 | 7.181 | -1.347 | 0.514 | 0 |
| Operating Expenses
| 147.011 | 120.25 | 76.577 | 48.485 | 40.093 |
| Operating Income
| -116.059 | -106.399 | -66.979 | -36.124 | -34.305 |
| Operating Income Ratio
| -3.366 | -7.682 | -6.978 | -2.922 | -5.927 |
| Total Other Income Expenses Net
| 14.182 | 7.048 | 0.377 | -0.003 | 3.337 |
| Income Before Tax
| -101.877 | -99.351 | -66.602 | -36.127 | -30.968 |
| Income Before Tax Ratio
| -2.955 | -7.173 | -6.939 | -2.923 | -5.35 |
| Income Tax Expense
| 0.193 | 0.07 | 0.321 | -1.819 | -7.537 |
| Net Income
| -102.07 | -99.421 | -66.923 | -34.308 | -23.431 |
| Net Income Ratio
| -2.961 | -7.178 | -6.973 | -2.776 | -4.048 |
| EPS
| -1.38 | -1.64 | -1.11 | -0.57 | -0.39 |
| EPS Diluted
| -1.38 | -1.64 | -1.11 | -0.57 | -0.39 |
| EBITDA
| -112.534 | -106.266 | -68.178 | -34.474 | -32.507 |
| EBITDA Ratio
| -3.264 | -7.672 | -7.103 | -2.789 | -5.616 |